Plasma Biomarkers May Help Target CAR-T Therapy for Multiple Myeloma
Researchers sought to determine whether plasma biomarkers may help enhance CAR-T therapy for patients with multiple myeloma.
CAR-T Therapy
Cytokine Release Syndrome Manageable in Relapsed/Refractory Multiple Myeloma Treated With CAR-T Therapy
Researchers sought to analyze the occurrence and severity of cytokine release syndrome in patients with relapsed/refractory multiple myeloma who recieve CAR-T therapy.
Neurotoxicity Associated With CAR-T Therapy
Neurotoxicity is common with CAR-T, occurring in 43% of patients in this multicenter, longitudinal study.
Risk Factors for Early Relapse of DLBCL After CAR-T Therapy
Nearly half of all relapses occurred within the first month of CAR-T infusion.
Anti-CD19 CAR T-Cell Therapy Effective in Relapsed/Refractory B-Cell Acute Lymphocytic Leukemia
Investigators aimed to determine and compare outcomes in patients with relapsed or refractory ALL who were treated with anti-CD19 CAR T-cell therapy.
Phase 1 Trial Featuring First shRNA-Edited CAR-T Therapy to Begin
FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.
Can Culturing CAR T Cells With Ibrutinib Improve Their Efficacy in CLL?
Sustained remission of CLL is associated with enrichment of a less-differentiated, early-memory phenotype of T cells in the apheresis product used to make CAR-T therapies.
Development of a Tool to Predict Neurotoxicity Associated With CAR-T Therapy
The occurrence, severity, and need for treatment of cytokine release syndrome were key parameters in the assessment of CAR-T–related neurotoxicity risk.
New NCCN Patient Guidelines Feature Immunotherapy, CAR-T Side Effects
The NCCN recently released 2 sets of Guidelines for Patients that explain the side effects of different types of immunotherapies, such as CAR T-cell therapies.
Early-Memory T-Cell Population May Predict CAR-T Efficacy in Several Hematological Malignancies
Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...